Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wuhan General Group (China), Inc. (WUHN)
Cape Town, NV, US
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The firm is also engages in research and development of indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. The company was founded by Xu Jie and Jeff Robinson on July 19, 1988 and is headquartered in Cape Town, South Africa.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -33.33% | -33.33% | -50.00% | +0.00% | +100.00% | +100.00% | -97.01% | -99.96% | -99.20% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-57.4%
-
EPS growth Medical - Pharmaceuticals: +20.2%-494.9%
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-11,715.3% Q3'22: +4,144.0%
-
EBIT margin Medical - Pharmaceuticals: +6.8%-12,040.1% Q3'22: -153,768.3%
-
ROIC Medical - Pharmaceuticals: +6.1%-308.3% Q3'22: +408.3%
-
Share dilution Medical - Pharmaceuticals: +0.0%+6.3%
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.05× Q3'22: 0.00×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carol Pan | Principal Financial Officer, Principal Accounting Officer and Treasurer | 60.0K | female |
| Clementine Toto | Head of African Aromatherapy | — | female |
| Huang Zhaoqi | Vice General Manager of Turbine and Director | — | male |
| Hyder Ali Khoja | Chief Scientific Officer | — | — |
| Jeffrey Robinson | Founder, Chairman & Chief Executive Officer | — | male |
| Nicola Royce | Managing Director of M2Biome | — | — |
| Samuel Williams | Head of Food Formulations & Functional Foods | — | male |
| Shivani Subudhi | Head of Marketing | — | female |
| Anna Leralta Morera | Chief Medical Officer | — | — |
| Willem Jonker | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WUHN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
